{"id":706760,"date":"2024-07-17T17:32:02","date_gmt":"2024-07-17T17:32:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=706760"},"modified":"2024-07-17T17:32:02","modified_gmt":"2024-07-17T17:32:02","slug":"drugcoated-balloons-market-to-reach-231-billion-by-2029-new-fda-approvals-propel-us-drugcoated-balloons-market-to-new-heights-exclusive-focus-insights-report-by-arizton","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/drugcoated-balloons-market-to-reach-231-billion-by-2029-new-fda-approvals-propel-us-drugcoated-balloons-market-to-new-heights-exclusive-focus-insights-report-by-arizton_706760.html","title":{"rendered":"Drug-Coated Balloons Market to Reach $2.31 Billion by 2029, New FDA Approvals Propel US Drug-Coated Balloons Market to New Heights – Exclusive Focus Insights Report by Arizton"},"content":{"rendered":"
\n
\"Drug-Coated<\/a><\/div>\n
\n
Drug-Coated Balloons Market Research Report by Arizton<\/div>\n<\/div>\n<\/div>\n

According to Arizton’s latest research report, the drug-coated balloons market<\/a> will grow at a CAGR of 15.72% during 2023-2029.<\/p>\n

 <\/p>\n

To Know More, Click: <\/strong>https:\/\/www.arizton.com\/market-reports\/drug-coated-balloons-market<\/a><\/p>\n

 <\/p>\n

Report Summary <\/strong> <\/p>\n

Market Size (2029): <\/strong>$2.31 Billion <\/strong> <\/p>\n

Market Size (2023): <\/strong>$965.41 Billion <\/p>\n

CAGR (2023-2029): <\/strong>15.72%  <\/p>\n

Historic Year: <\/strong>2020-2022 <\/p>\n

Base Year: <\/strong>2023 <\/p>\n

Forecast Year: <\/strong>2024-2029 <\/p>\n

Market Segmentation:<\/strong> Indication, Drug, End-Users, and Geography<\/p>\n

Geographical Analysis: <\/strong>North America, Europe, APAC, Latin America, and Middle East & Africa <\/p>\n

 <\/strong><\/p>\n

Stay ahead of the curve with Arizton’s exclusive subscription plan, offering in-depth analysis, market sizing, and growth forecasts for less than $900 per month—a significant value compared to individual report purchases. Click here<\/strong>: <\/strong>https:\/\/www.arizton.com\/subscription<\/strong><\/a>\u202f\u202f\u202f<\/strong>\u202f <\/p>\n

 <\/p>\n

The US Leads North America in Drug-Coated Balloons Market with Major Revenue Contribution<\/strong><\/p>\n

In 2023, the US accounted for an impressive 93.59% share of the North America drug-coated balloons market, solidifying its position as the leading market in the region. Globally, the US held more than 40% of the market share and emerged as the major revenue contributor to the global drug-coated balloons market, with a value of $477.58 million.<\/p>\n

The growing demand for drug-coated balloons is largely driven by the increasing prevalence of heart diseases, peripheral artery disease (PAD), coronary artery disease (CAD), failing arteriovenous fistulas, and other related health conditions. These conditions come with significant health expenditures, making drug-coated balloons a preferred alternative to traditional stenting procedures. The Centers for Disease Control and Prevention (CDC) reported that in 2023, the annual cost of heart diseases was estimated at around $239 billion, highlighting substantial revenue growth opportunities for vendors in the US market.<\/p>\n

In 2023, more than 21 million individuals in the US were estimated to be affected by PAD, with limited alternative treatments available for its management. Most US healthcare settings prefer drug-coated balloon (DCB) insertion for PAD management due to its safety and efficacy. Additionally, cardiovascular diseases remain the leading cause of death in the country, with the CDC revealing that over 21 million adults in the US have CAD. Annually, around 366,000 people die from CAD, and over 800,000 new cases of cardiovascular diseases are registered.<\/p>\n

The rising burden of PAD and CVD is significantly driven by diabetes, with over 39 million people in the US estimated to have diabetes in 2023. Diabetic patients face a 2-to-4-fold increased risk of heart diseases, further amplifying the need for effective treatment options like balloon angioplasty procedures.<\/p>\n

The demand for balloon angioplasty procedures is rising in the US, with more than 1 million coronary angioplasty procedures performed annually, contributing to market growth. Additionally, over 9 million peripheral vascular procedures are conducted each year in the country. Atherectomies, a minimally invasive procedure often performed with a balloon, are also prevalent, with more than 190,000 procedures performed annually.<\/p>\n

The growing prevalence of leading diseases that necessitate balloon angioplasty procedures and associated health expenditures are significantly driving market growth in the US. As the demand for drug-coated balloons continues to rise, the US remains at the forefront of this expanding market, providing ample opportunities for innovation and revenue generation.<\/p>\n

 <\/strong><\/p>\n

Recent Approvals & Launches of DCBs<\/strong><\/p>\n